Longitudinal MR-based proton-density fat fraction (PDFF) and T2* for the assessment of associations between bone marrow changes and myelotoxic chemotherapy.

Felix G GassertJulia KranzFlorian T GassertBenedikt J SchwaigerChristian BognerMarcus R MakowskiLeander GlanzJonathan StelterThomas BaumRickmer BrarenDimitrios C KarampinosAlexandra S Gersing

Published in: European radiology (2023)

Quantifying changes in bone marrow fat fraction, as well as T2* caused by myelotoxic pharmaceuticals using proton density fat fraction, is feasible. Proton density fat fraction could potentially be established as a non-invasive biomarker for early bone marrow changes in oncologic patients undergoing myelotoxic treatment.

Keyphrases

bone marrow
adipose tissue
mesenchymal stem cells
patients undergoing
fatty acid
radiation therapy
rectal cancer
minimally invasive
contrast enhanced
smoking cessation
replacement therapy